Last reviewed · How we verify
YL-13027，Sintilimab
At a glance
| Generic name | YL-13027，Sintilimab |
|---|---|
| Also known as | YL-13027 tablet，Sintilimab injection |
| Sponsor | Shanghai YingLi Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL-13027，Sintilimab CI brief — competitive landscape report
- YL-13027，Sintilimab updates RSS · CI watch RSS
- Shanghai YingLi Pharmaceutical Co. Ltd. portfolio CI